726-17-0

Basic information

• Product Name: 4-(4-Nitrobenzyl)aniline
• Synonyms: 4-(4-Nitrobenzyl)aniline;4-[(4-Nitrophenyl)methyl]aniline
• CAS NO: 726-17-0
• Molecular Formula: C₁₃H₁₂N₂O₂
• Molecular Weight: 228.2466
• Mol File: 726-17-0.mol

Chemical Properties

• Boiling Point: 417.7°Cat760mmHg
• Flash Point: 206.4°C
• Appearance: /
• Density: 1.247g/cm³
• Vapor Pressure: 3.48E-07mmHg at 25°C
• Refractive Index: 1.645
• CAS DataBase Reference: 4-(4-Nitrobenzyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Nitrobenzyl)aniline(726-17-0)
• EPA Substance Registry System: 4-(4-Nitrobenzyl)aniline(726-17-0)

Safety Data

• Hazardous Substances Data: 726-17-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H12N2O2/c14-12-5-1-10(2-6-12)9-11-3-7-13(8-4-11)15(16)17/h1-8H,9,14H2

Upstream product

• 1817-74-9 bis(4-nitrophenyl)methane 
• 100-63-0 phenylhydrazine 
• 228401-19-2 4-(4-(tert-butoxycarbonylamino)phenyl)methyl-1-nitrobenzene 
• 100-14-1 4-nitrobenzyl chloride 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 6665-60-7 N-acetyl-4′-amino-4-nitrodiphenylmethane 

Downstream Products

• 1155287-72-1 6-(4-Nitro-benzyl)-benzothiazol-2-ylamine 

Relevant articles and documents

Synthetic approaches to obtain amino acid adducts of 4,4′- methylenediphenyl diisocyanate

4,4′-Methylenediphenyl diisocyanate (MDI) is the most important isocyanate used in the chemical industry. Lung sensitization and asthma are the main types of damage after exposure to MDI. Albumin adducts of MDI might be involved in the etiology of sensitization reactions. It is therefore necessary to have sensitive and specific biomarkers such as blood protein adducts to monitor people exposed to isocyanates. For the discovery of new isocyanate adducts with blood proteins present in vivo, new synthetic standards are needed. To achieve this, we developed five methods to obtain amino acid adducts of MDI. We synthesized and isolated MDI adducts of aspartic acid, glutamic acid, cysteine, and valine. The new adducts were characterized by LC-MS/MS and NMR. We synthesized the corresponding isotope-labeled MDI adducts to develop analytical methods using LC-MS/MS. Glutathione adducts of isocyanates are an important way of transportation of the reactive isocyanates to distant sites from the original site of exposure. Therefore, we used N-acetyl-cysteine adducts of MDI as reactants: N-acetyl-S-[[4-(4-aminobenzyl)phenyl]carbamoyl]-cysteine (MDI-AcCys) and N-acetyl-S-[[4-(4-acetylaminobenzyl)phenyl]carbamoyl]-cysteine (AcMDI-AcCys). MDI-AcCys or AcMDI-AcCys formed adducts with albumin, N α-acetyl lysine, and valine. Isotope-labeled albumin adducts (= d4-MDI-albumin) were synthesized from d4-MDI-AcCys and albumin. d4-MDI-albumin can be used as an internal standard to analyze biological samples. Such an internal standard will not correct only for the extraction recovery of the adducts but also for the potential variation of the enzymatic digestions used in the procedure to analyze albumin adducts of MDI. The synthetic procedures described in this manuscript will be applicable to the synthesis of amino acid adducts from other isocyanates.

SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS

The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles. A particular embodiment is

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Palladium-catalyzed silane/siloxane reductions in the one-pot conversion of nitro compounds into their amines, hydroxylamines, amides, sulfonamides, and carbamates

A combination of palladium(II) acetate, aqueous potassium fluoride, and polymethylhydrosiloxane (PMHS) facilitates the room-temperature reduction of aromatic nitro compounds to anilines. These reactions tend to be quick (30 min), high-yielding, and tolerate a range of other functional groups. Replacement of PMHS/KF with triethylsilane allows for the reduction of aliphatic nitro compounds to their corresponding hydroxylamines. Depending on the substrate, both conditions can allow for the in situ conversion of the product amines into amides, sulfonamides, and carbamates. Georg Thieme Verlag Stuttgart.

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.